• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作者更正:HER2和HER3突变型癌症患者中的HER激酶抑制作用

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

作者信息

Hyman David M, Piha-Paul Sarina A, Won Helen, Rodon Jordi, Saura Cristina, Shapiro Geoffrey I, Juric Dejan, Quinn David I, Moreno Victor, Doger Bernard, Mayer Ingrid A, Boni Valentina, Calvo Emiliano, Loi Sherene, Lockhart Albert C, Erinjeri Joseph P, Scaltriti Maurizio, Ulaner Gary A, Patel Juber, Tang Jiabin, Beer Hannah, Selcuklu S Duygu, Hanrahan Aphrothiti J, Bouvier Nancy, Melcer Myra, Murali Rajmohan, Schram Alison M, Smyth Lillian M, Jhaveri Komal, Li Bob T, Drilon Alexander, Harding James J, Iyer Gopa, Taylor Barry S, Berger Michael F, Cutler Richard E, Xu Feng, Butturini Anna, Eli Lisa D, Mann Grace, Farrell Cynthia, Lalani Alshad S, Bryce Richard P, Arteaga Carlos L, Meric-Bernstam Funda, Baselga José, Solit David B

机构信息

Memorial Sloan Kettering Cancer Center, New York, New York, USA.

University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Nature. 2019 Feb;566(7745):E11-E12. doi: 10.1038/s41586-019-0974-0.

DOI:10.1038/s41586-019-0974-0
PMID:30755741
Abstract

The 'Competing interests' statement of this Article has been updated; please see the accompanying Amendment. The original Article has not been corrected online.

摘要

本文的“利益冲突”声明已更新;请参阅随附的修订案。原始文章尚未在网上更正。

相似文献

1
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.作者更正:HER2和HER3突变型癌症患者中的HER激酶抑制作用
Nature. 2019 Feb;566(7745):E11-E12. doi: 10.1038/s41586-019-0974-0.
2
Author Correction: Targeted therapy in patients with PIK3CA-related overgrowth syndrome.作者更正:PIK3CA相关过度生长综合征患者的靶向治疗
Nature. 2019 Apr;568(7752):E6. doi: 10.1038/s41586-019-1109-3.
3
Author Correction: Multi-trait analysis of genome-wide association summary statistics using MTAG.作者更正:使用MTAG对全基因组关联汇总统计数据进行多性状分析。
Nat Genet. 2019 Aug;51(8):1295. doi: 10.1038/s41588-019-0469-9.
4
Author Correction: c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont.作者更正:依赖c-MAF的调节性T细胞介导对肠道病原菌的免疫耐受。
Nature. 2019 Feb;566(7744):E7. doi: 10.1038/s41586-019-0922-z.
5
Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?激酶失活的HER3的转磷酸化与乳腺癌进展:新观点还是旧概念的重新审视?
Breast Cancer Res. 2007;9(5):111. doi: 10.1186/bcr1773.
6
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.激酶失活的HER3介导的HER家族酪氨酸激酶抑制剂治疗逃逸
Nature. 2007 Jan 25;445(7126):437-41. doi: 10.1038/nature05474. Epub 2007 Jan 7.
7
Author Correction: Linkage disequilibrium-dependent architecture of human complex traits shows action of negative selection.
Nat Genet. 2019 Aug;51(8):1295. doi: 10.1038/s41588-019-0468-x.
8
HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285.HER2和HER3协同调节癌细胞生长,并决定对新型研究性EGFR/HER2激酶抑制剂TAK-285的敏感性。
Oncoscience. 2014 Mar 24;1(3):196-204. doi: 10.18632/oncoscience.23. eCollection 2014.
9
Author Correction: CasX enzymes comprise a distinct family of RNA-guided genome editors.作者更正:CasX酶构成了一个独特的RNA引导基因组编辑器家族。
Nature. 2019 Apr;568(7752):E8-E10. doi: 10.1038/s41586-019-1084-8.
10
A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.HER3在HER2扩增和非扩增乳腺癌中的关键作用:一种激酶失活型受体酪氨酸激酶的功能
Am J Transl Res. 2015 Apr 15;7(4):733-50. eCollection 2015.

引用本文的文献

1
The present and future of precision oncology and tumor-agnostic therapeutic approaches.精准肿瘤学与肿瘤非特异性治疗方法的现状与未来。
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf152.
2
Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2.中国大规模患者结直肠癌的基因组分析:ERBB2 的扩增和体细胞突变。
Oncol Res. 2024 Aug 23;32(9):1429-1438. doi: 10.32604/or.2024.047309. eCollection 2024.
3
Integrated Workflow for the Label-Free Isolation and Genomic Analysis of Single Circulating Tumor Cells in Pancreatic Cancer.
用于胰腺癌中无标记循环肿瘤细胞的分离和基因组分析的集成工作流程。
Int J Mol Sci. 2022 Jul 16;23(14):7852. doi: 10.3390/ijms23147852.
4
Negative Ultraselection of Patients With / Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.抗 EGFR 治疗的野生型、微卫星稳定转移性结直肠癌患者的负超选择。
JCO Precis Oncol. 2022 Apr;6:e2200037. doi: 10.1200/PO.22.00037.
5
Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis.曲妥珠单抗联合紫杉类药物治疗 HER2 阳性转移性乳腺癌的有效性和安全性的 Meta 分析。
Br J Clin Pharmacol. 2022 May;88(5):2019-2034. doi: 10.1111/bcp.15155. Epub 2021 Dec 21.
6
Genomic Characterization of -Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine.-驱动的胆管癌的基因组特征及一例对ado曲妥珠单抗恩杂鲁胺的反应
JCO Precis Oncol. 2019 Oct 17;3. doi: 10.1200/PO.19.00223. eCollection 2019.